secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001439222-25-000076
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Agios Pharmaceuticals elects Jay Backstrom, M.D., MPH to board
--------------------------------------------------------------

- Dr. Backstrom appointed as Class III director, term until 2028 Annual Meeting.
- Appointed to Science and Technology Committee of the Board effective July 8, 2025.
- Initial compensation includes stock option with $472,500 Black-Scholes value and RSUs valued at $157,500.
- Annual cash compensation: $50,000 for board service plus $7,500 for committee service, quarterly pro-rata.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922225000076/0001439222-25-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922225000076/agio-20250703.htm
  HTML page:      https://secwatch.observer/filing/0001439222-25-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer